(-)-(S)-B-973B is a novel and potent allosteric agonist and positive allosteric modulator of α7 nAChR, with antinociceptive activity.

Nelonicline (aslo known as ABT-126) is a novel, potent and selective neuronal nicotinic receptor agonist.

TMPH inhibitor(also known as nAChR-IN-1) is a potent and selective nicotinic acetylcholine receptor (nAChR) inhibitor.

NS-3861 is a novel and potent α3β2 nAChR full agonist and an α3β4 partial agonist (Ki = 0.62 nM).

Varenicline (also known as CP 526555), an approved medication used to treat nicotine addiction, is a potent and selective α4β2 nicotinic receptor (nAChR) partial agonist.

PNU282987 is a novel selective agonist of the alpha7 nAChR, evoked whole-cell currents from cultured rat hippocampal neurons that were sensitive to the selective alpha7 nAChR antagonist methyllycaconitine (MLA) and enhanced GABAergic synaptic activity when applied to hippocampal slices.

Sofiniclin (formerly also known as ABT-894 and A-422894) is a novel and potent agonist of nicotinic acetylcholine receptor (nAChR) which is used as a potential non-stimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

Varenicline dihydrochloride is a nicotinic receptor partial agonist.

Meclofenoxate (also known as Centrophenoxine) HCl is a potent nootropic agent and an anti-aging drug used to treat the symptoms of senile dementia and Alzheimer’s disease, and also inhibits the activity of cholinephosphotransferase.

AVL-3288 (UCI-4083; UCI4083; CCMI; XY-4083; Anvylic-3288; AVL3288) is an orally bioavailable and selective allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR) with neuroprotective effects.